Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Cisplatin, and Radiation in Vulvar Squamous Cell Carcinoma
NCT04430699Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2020
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in vulvar squamous cell carcinoma (VSCC), sponsored by Massachusetts General Hospital. Started Jul 2020; status: active, not recruiting.
02
Drugs
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT04430699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04430699.